Dr Cath O’Neill
CEO, SkinBioTherapeutics plc
12:00 - 12:45
Patently biased, sponsored by Arm
Cath is a senior lecturer at the University of Manchester in the Dermatological Sciences Research group. As an academic, her research work is very translational and focuses on new therapies for skin in health and disease. This translational approach has led to the creation of two spin out companies: Curapel in 2011 and more recently, SkinBiotix in March 2016, which subsequently became SkinBioTherapeutics plc. In April of this year, Cath gained a secondment from the university in order to lead SkinBioTherapeutics plc through a successful IPO and the company listed on the AIM market in april. Having raised £4.5M Cath now divides her time between the company and her academic research at the university.